The "Oncology Collaboration and Licensing Deals 2020-2025" has been added to ResearchAndMarkets.com's offering.
Fully revised and updated, the report provides details of 3,350 oncology deals from 2020 to 2025.
Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the oncology deals entered into by the world's leading biopharma companies. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 introduces the report, while Chapter 2 analyzes trends in oncology dealmaking. Chapter 3 outlines the financial deal terms in the oncology field, organized by various financial metrics. Chapter 4 reviews the top 25 biopharma companies active in oncology dealmaking, providing contract access when available. Chapter 5 provides details of oncology deals since 2020, linking to available contract documents. Chapter 6 offers a directory of oncology deals categorized by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in oncology deal making since 2020. In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2020
- Browse oncology collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Oncology Collaboration and Licensing Deals includes:
- Trends in oncology dealmaking in the biopharma industry
- Overview of collaboration and licensing deal structure
- Directory of oncology deal records covering pharmaceutical and biotechnology
- The leading oncology deals by value
- Most active oncology licensing dealmakers
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in oncology dealmaking
2.1. Introduction
2.2. Oncology partnering over the years
2.3. Oncology partnering by deal type
2.4. Oncology partnering by industry sector
2.5. Oncology partnering by stage of development
2.6. Oncology partnering by technology type
2.7. Oncology partnering by therapeutic indication
Chapter 3 - Financial deal terms for oncology partnering
3.1. Introduction
3.2. Disclosed financials terms for oncology partnering
3.3. Oncology partnering headline values
3.4. Oncology deal upfront payments
3.5. Oncology deal milestone payments
3.6. Oncology royalty rates
Chapter 4 - Leading oncology deals and dealmakers
4.1. Introduction
4.2. Most active in oncology partnering
4.3. List of most active dealmakers in oncology
4.4. Top oncology deals by value
Chapter 5 - Oncology contract document directory
5.1. Introduction
5.2. Oncology partnering deals where contract document available
Chapter 6 - Oncology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by oncology therapeutic target
Deal directory
- Deal directory - Oncology deals by company A-Z 2020 to 2025
- Deal directory - Oncology deals by technology type 2020 to 2025
- Deal type definitions
Companies Featured (Partial List)
- 1ST Biotherapeutics
- 2cureX
- 2seventy bio
- 3B Pharmaceuticals
- 3D Medicines
- 3SBio
- 3T Biosciences
- 4baseCare
- 4bases
- 4C Biomed
- 4D Path
- 4D Pharma
- 7 Hills Pharma
- 9 Meters Biopharma
- 48Hour Discovery
- Abbisko Therapeutics
- Abbott Laboratories
- Abbvie
- Abcam
- AbCellera Biologics
- Accent Therapeutics
- Accuray
- AccuStem Sciences
- ACEA Therapeutics
- Acepodia
- Adagene
- ADC Therapeutics
- Adaptimmune
- Adaptive Biotechnologies
- Aeglea BioTherapeutics
- Aegirbio
- Agendia
- Agenus Bio
- AgeX Therapeutics
- Agilent Technologies
- AiCure
- Aidence
- Aikido Pharma
- AI Longevity
- AimedBio
- AIM ImmunoTech
- Ainos
- Aion Therapeutic
- AI Proteins
- Aitia
- Akamis Bio
- AKSO Biopharmaceutical
- Alamar Biosciences
- Alaya.bio
- Albany Medical College
For more information about this report visit https://www.researchandmarkets.com/r/e5iy1r
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250701781539/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900